FDA approves ibrutinib for the treatment of chronic graft-versus-host disease ( cGVHD ) in children

Classification： Company News

Publication：2022-09-25 09:30

Syncozymes's annual production of 100 tons of coenzyme NMN/NADH/NAD series products will be officially put into production in October this year!

On August 24, 2022, the U.S. Food and Drug Administration (FDA) approved ibrutinib for the treatment of pediatric patients older than 1 year with chronic graft-versus-host disease ( cGVHD ) who are receiving After failure of 1- or multi-line systemic therapy . The approved indication is mainly for pediatric patients, with an overall response rate of 60% at week 25, and the drug formulations include capsules, tablets and oral suspensions.

Ibrutinib , a BTK inhibitor co-developed by Pharmacyclics/Johnson & Johnson, is a kinase inhibitor previously approved for the treatment of chronic lymphocytic leukemia as well as cell lymphoma and other diseases .

Suntech focuses on the development and production of pharmaceutical intermediates and APIs using green technology. At present, our company has developed three intermediate products of ibrutinib including C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , all of which have been commercialized in GMP factories production. Among them, the intermediate of C AS: 143900-44-1 is produced by chemical-enzymatic technology , which has the advantages of green environmental protection, low price and high quality. Welcome to consult and cooperate!

Next: Big news: Syncozymes has an annual output of 100 tons of coenzyme NMN/NADH/NAD series. These ingredients will be put into production

Leave a Message Online